transplant donors on routine pretransplant assessment. Tonsillar tissue came from elective tonsillectomies while spleens came from patients undergoing surgery for traumatic rupture or immune thrombocytopenic purpura. Mononuclear cell (MNC) fractions were separated on Ficoll-Hypaque (specific gravity, 1.078). Cells from bone marrow aspirates were then depleted of adherent cells and washed repeatedly to remove any cytophilic Ig.
Human Cell Lines. LICR LON/HMy2 (HMy2) came from the Ludwig Institute of Cancer Research (LICR), London; JURKAT was obtained from Dr. J. Watson, Medical School, Auckland University, Auckland, New Zealand and other cell lines came from LICR, Sydney.
Surface hnmunofluorescent Staining. Cells were suspended at 2 x 107 cells/ml in RPMI containing 0.02% (wt/vol) sodium azide (RPMI-NaN~). Aliquots (100 •1) were incubated (o) with 100 ul of a 1:10 dilution of fluorescein isothiocyanate (FITC)-sheep F(ab')2 antihuman Ig heavy or light chain specific antisera (Kallestad Laboratories, Inc., Austin, TX) or (b) with 100 ul of K-l-21 or control IgG monoclonal antibodies (at 1 mg/ml) followed by 100 IA of a 1:50 dilution of FITC-sheep F(ab')~ anti-mouse Ig (New England Nuclear, Boston, MA). All incubations were for 30 min at 4°C followed by two washes with cold RPMI-NaN3. Stained cells were resuspended in 10% phosphate-buffered saline (PBS) in glycerol, pH 8.6, and mounted for examination under a Zeiss photomicroscope II (Carl Zeiss, Oberkochen, Federal Republic of Germany).
Fluorescence-activated Cell Sorter (FACS) III Analysis. Aliquots of washed HMy2 cells (2 X 10 6 cells in 100 #1) were exposed for 30 min at 4°C to 50 #g of K-l-21 alone or to K-1-21 preincubated with 620 ug VOR or MOS BJ Proteins or to 1,820 t~g of normal human IgG. After washing twice in cold RPMI-NaN~, the cells were incubated for 30 min at 4°C with 100 ul FITC-sheep F(ab')~ anti-mouse Ig (New England Nuclear, Boston, MA) at a 1:50 dilution in PBS, pH 7.2. After two washes in cold PBS-NaNs, individual samples were analyzed on a FACS III (Becton, Dickinson & Co., Mountain View, CA).
Results K-1-21 is a hybrid cell line secreting an IgG1 kappa monoclonal antibody that binds all free monomers and disulphide-bonded dimers of human kappa light chains (Table I) . No reactivity was seen with free lambda light chains, intact Ig molecules, or human serum albumin. Binding was unaffected by periodic acid treatment of the antigen, indicating that the antibody does not recognize a carbohydrate determinant.
The cell surface distribution of the K-l-21 reactive determinant, KMA, was examined by immunofluorescence of MNC from normal individuals and from patients with a variety of B or T cell malignancies. Two IgG monoclonal antibodies of irrelevant specificity were used as controls and always failed to show any cell surface staining.
K-1-21 antibody did not bind to the surface of normal MNC (Table II) . It also failed to react with PBM from patients with kappa myeloma or to PBM or bone marrow plasma cells from patients with lambda myeloma and a variety of nonmyelomatous conditions, despite the presence in the latter samples of varying numbers of plasma cells reactive with polyvalent anti-kappa serum (Table II) . On the other hand, plasma cells in bone marrow aspirates from eight out of 11 patients with kappa myeloma showed strong fluorescent staining with K-l-21. The proportion of K-l-21-positive plasma cells varied greatly, ranging from 9 to 78% of total plasma cells. Of the three cases where cells did not stain with K-l-21, two were IgG kappa myelomas and the third was an IgA kappa. While cells from one of the IgG kappa secretors also failed to react with polyvalent antikappa or anti-Ig sera, anti-kappa antisera did stain 86 and 85%, respectively, of plasma cells from the remaining two patients. Also, BJP from these patients Binding of K-1-21 was assessed by indirect solid-phase RIA. Antigens tested were adsorbed onto polyvinyl plates. After blocking with bovine serum albumin, purified K-l-21 was added, followed by ~25I-rabbit antimouse Ig; radioactivity bound on each well was counted on a gamma spectrometer. * Number reactive per number tested. * Cells were stained with K-1-21 or a control monoclonal followed by FITC-sheep F(ab')2 anti-mouse Ig. s Cells were stained with FITC-goat anti-human kappa antiserum. The numbers of kappa-reactive cells fall within the expected normal range for each cell population examined. 0 The five nonmyelomatous bone marrows were: amyloid of Ig origin (52% kappa-reactive plasma cells), IgG kappa benign paraproteinaemia (50% kappa), systemic lupus erythrematosus (40% kappa), B CLL in remission (18% kappa), and acute myeloid leukemia (12% kappa). ! Number reactive per number examined.
Not done. displayed strong reactivity with K-l-21 in an indirect RIA, indicating that a K-I-21-reactive determinant was present on the secreted cell products.
Further analysis of the KMA expression was carried out on human cell lines (Table III) . Of these, only HMy2, derived from an IgG kappa myeloma (5), reacted with K-l-21.
The specificity of K-l-21 binding to HMy2 cells was examined by flow cytometry. HMy2 cells were incubated with K-l-21 alone or with K-1-21 preincubated with normal human IgG or with lambda (MOS) or kappa (VOR) BJP. The cells were then incubated with FITC-sheep F(ab')2 anti-mouse Ig. Upon FACS analysis, HMy2 cells incubated with K-l-21 exhibited strong cell surface reactivity (Fig. 1) . However, on exposure to K-l-21 preincubated with VOR kappa light chains, the fluorescence curve was shifted sharply to the left. No apparent diminution in fluorescence intensity occurred when K-l-21 was preincubated with equivalent amounts of lambda light chain or with human IgG.
Discussion
The IgG~ monoclonal antibody K-l-21 described here recognizes an epitope on dimers and monomers of free human kappa light chains but fails to react with intact Ig. Cell surface binding studies of K-1-21 antibody revealed an epitope, KMA, with tumor-specific properties. Thus, K-l-21 bound strongly to the surface of plasma cells from 8 of 11 patients with kappa myeloma but failed to react with plasma cells from normal individuals or from patients with lambda myeloma or nonmyeiomatous conditions. Furthermore, no binding was observed to PBM from normal donors or from patients with chronic lymphocytic leukemia (CLL), myeloma, or macroglobulinaemia, or to MNC from normal secondary lymphoid tissue. Present evidence thus suggests that KMA may be regarded in an operational sense as a tumor marker with specificity for kappa myeloma cells.
The proportion of plasma cells in the bone marrow that could be labeled with K-l-21 varied greatly. On the basis of flow cytometry analysis, this appears to be related to the cycling characteristics of the tumor at the time of sampling rather than to a true lack of expression of KMA (unpublished observations). Predictably, therefore, BJP from the two patients whose bone marrow cells failed to bind K-1-21, but did react with a polyvalent anti-kappa antiserum, displayed strong reactivity with the monoclonal antibody in an indirect RIA.
Further analysis of KMA expression was carried out with a panel of human cell lines. Convincing cell surface reactivity was only observed in the IgG kappa myeloma line HMy2, the one myeloma line included in the panel, whereas cells from all other lines were negative. The specificity of binding of K-l-21 was confirmed in inhibition studies with FACS Ill analysis. When HMy2 cells were exposed to K-l-21 antibody that had been preincubated with purified VOR kappa light chains, complete inhibition of binding occurred, whereas no comparable diminution in fluorescence intensity occurred after preincubation with equivalent amounts of lambda light chain or with human IgG.
These results raise the interesting question of the nature of the K-1-21-reactive determinant on the cell membrane. Since K-l-21 reacts with kappa light chains in free form but not with kappa chains associated with intact Ig molecules, KMA may be an epitope on kappa chains inserted as free entities in the cell membrane of myeloma cells. Consistent with this interpretation is the demonstration of free light chains on the surface of certain murine plasmacytoma cells (6) and their absence on normal mouse spleen cells (7) . However, it is also possible that K-l-21 may recognize a cross-reactive determinant on a molecule other than free kappa light chains that is unique to the membrane of kappa myeloma cells. Cross-reactivity of this type has been demonstrated with a number of monoclonal antibodies (8) .
Summary A monoclonal antibody (K-l-21) raised against a kappa Bence Jones protein exhibits unique binding properties to malignant plasma cells. K-l-21 is an IgG1 kappa antibody that reacts with human kappa light chains in free form, but shows no reactivity with heavy chain-associated kappa light chains. By immunofluorescence, K-l-21 binds to the surface of LICR LON/HMy2 (HMy2) kappa myeloma cells and to plasma cells from a majority (8/11) of patients with various types of kappa myeloma; it did not bind to the surface of normal cells, nor to malignant cells of non-kappa myeloma origin. Flow cytometry analysis of K-l-21 binding to HMy2 cells indicated that the surface reactivity of K-l-21 could be completely inhibited by preincubation of the antibody with purified kappa light chains, whereas no inhibition occurred after preincubation with lambda chains or intact human IgG. Thus, the epitope recognized by K-l-21 on the cell surface may be similar, if not identical, to the determinant recognized on soluble free kappa light chains, and constitutes a tumor-associated antigen with selectivity for kappa myeloma cells. K-l-21 may therefore have clinical potential in patients with kappa myeloma.
